Session » RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1646

Abnormal Cerebrovascular Biomarkers in Patients with Rheumatoid Arthritis: Results from a Prospective Study of Cognitive Aging

8:30AM-10:30AM: Abstract Number: 1666

Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthritis Disease Activity

8:30AM-10:30AM: Abstract Number: 1664

Changes in Physical Function Were Not Associated with Clinically Important Changes in Muscle Strength or Physical Performance over Time – A Cohort Study

8:30AM-10:30AM: Abstract Number: 1654

Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL

8:30AM-10:30AM: Abstract Number: 1657

Comprehensive Assessment of Multimorbidity Burden in a Population-based Cohort of Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1671

COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City

8:30AM-10:30AM: Abstract Number: 1667

Efficacy of Plasma Phosphoethanolamine as a Biomarker for Rheumatoid Arthritis-associated Depression

8:30AM-10:30AM: Abstract Number: 1645

Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1650

Identifying Trajectories and Endotypes in the Evolution of Pre-Rheumatoid Arthritis with Autoantibody Testing and Artificial Adaptive System Analysis

8:30AM-10:30AM: Abstract Number: 1659

Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthritis After First Antidepressant Dispensing: Results from the Nationwide DANBIO Database

8:30AM-10:30AM: Abstract Number: 1670

Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

8:30AM-10:30AM: Abstract Number: 1648

Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1647

Interaction Effect of Systemic Inflammation and Dietary Protein Intake on Resting Energy Expenditure in Individuals with RA

8:30AM-10:30AM: Abstract Number: 1672

Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA

8:30AM-10:30AM: Abstract Number: 1669

Minimal Erosive Volume Needed for Radiographic Identification of Erosions in the Metacarpophalangeal Joints in Rheumatoid Arthritis. a Comparative Analysis of High Resolution Peripheral Quantitative Computed Tomography and Conventional Radiography

8:30AM-10:30AM: Abstract Number: 1649

Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder

8:30AM-10:30AM: Abstract Number: 1665

Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1653

Positron Emission Tomography-Detected Uptake of 18F-Fluorodeoxyglucose in Visceral and Subcutaneous Adipose Tissue Is Associated with Articular Disease Activity and Arterial Inflammation in Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1660

Relationship Between Risk of New Onset Diabetes Mellitus and Exposure to Individual Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study

8:30AM-10:30AM: Abstract Number: 1673

Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions

8:30AM-10:30AM: Abstract Number: 1658

Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1655

Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients

8:30AM-10:30AM: Abstract Number: 1661

Sex-Stratified Patterns of Multimorbidity at RA Onset and Associated Longitudinal Impacts on Disability Over the First Year Follow Up: Results from the Canadian Early Arthritis Cohort (CATCH)

8:30AM-10:30AM: Abstract Number: 1652

Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1651

Symptom Trajectories in the Transition from Pre-Rheumatoid Arthritis to Clinically-Apparent Inflammatory Arthritis

8:30AM-10:30AM: Abstract Number: 1663

The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia

8:30AM-10:30AM: Abstract Number: 1668

Unmet Need in Early Rheumatoid Arthritis – Why Do Some Patients Do Badly Despite Modern Treat-to-target Strategies of Care? Results from the Scottish Early RA (SERA) Inception Cohort

8:30AM-10:30AM: Abstract Number: 1662

Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection

8:30AM-10:30AM: Abstract Number: 1656

Women with Rheumatoid Arthritis Have More Multimorbidity Than Men in a Large Nationwide US Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].